Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Sonnet BioTherapeutics Holdings ( (SONN) ) has issued an announcement.
On February 19, 2025, Sonnet BioTherapeutics announced advancements in its proprietary Antibody Drug Conjugate (ADC) platform, designed to address technical challenges in ADC development. The platform, now available for drug discovery partnerships, aims to produce multiple drug candidates. The initial proof-of-concept, SON-5010, demonstrated similar activity to existing treatments in preclinical studies, indicating potential for novel ADCs with flexible payloads and tumor targeting capabilities.
More about Sonnet BioTherapeutics Holdings
Sonnet BioTherapeutics Holdings, Inc. is an oncology-focused biotechnology company developing targeted biologic drugs with single or bifunctional action. The company utilizes its proprietary FHAB platform to create large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines, specifically targeting tumor and lymphatic tissue to optimize safety and efficacy.
YTD Price Performance: -4.38%
Average Trading Volume: 1,070,464
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.69M
Find detailed analytics on SONN stock on TipRanks’ Stock Analysis page.
